Editorial: The Promise of Extracellular Vesicles as Biomarkers for Early Detection of Cancer

Cancer remains one of the leading causes of morbidity and mortality worldwide, with early detection playing a crucial role in improving patient outcomes. Traditional diagnostic methods, such as Complete Blood Counts (CBC), imaging and tissue biopsies, often fall short in terms of sensitivity and specificity, particularly in the early stages of carcinogenesis. The evolving field of liquid biopsies, especially the bioactive molecules expressed in the extracellular vesicles (EVs), has emerged as a promising avenue for the early detection and monitoring of various cancers. This editorial discusses the potential of EV-based biomarkers, their mechanisms of action, and the current clinical implications in oncology.

Understanding EVs

EVs are lipid bilayer structures released by every cell types into the extracellular environment. They include exosomes or small extracellular vesicles (sEVs; 30-150 nm in diameter), microparticles (100-1,000 nm), and apoptotic bodies (>1 µm).^{1, 2} EVs play pivotal roles in intercellular communication and can carry proteins, lipids, and nucleic acids, reflecting the pathophysiological condition of their parent cells.^{1, 2}

Mechanisms of Cancer Progression via EVs

Cancer cells exploit EVs to communicate with surrounding cells and tissues, facilitating tumor growth, metastasis, and immune evasion. The cargo within EVs contains various bioactive molecules, including oncogenes, tumor suppressor genes, and microRNAs (miRNAs), which can modulate the behavior of recipient cells. For instance, studies have shown that miRNAs within EVs can induce phenotypic changes in recipient cells, contributing to a more conducive tumor microenvironment. ³ Unfortunately, most current miRNA biomarkers are unlikely to have much clinical utility. As we and others have shown, strategies for identifying miRNA biomarkers in the first wave of discovery were inadequate and challenged by variable isolation methods, non-standard analysis designs, and an underappreciation of the cellular source of a miRNA.^{4, 5} Despite these problems, these studies have taught us that the most specific and reproducible miRNA biomarkers will be those identified in EVs. ⁶ However, as characterized before, blood EVs are comprised of sEVs, microparticles that originate from a variety of cellular sources. These different bodies are variable between individuals and disease states, which significantly impacts the relative amounts of miRNAs they contain, as many miRNAs are cell-type specific. Thus, a measure of general blood-derived EV miRNA may simply reflect altered ratios of EV cellular sources rather than a true change in miRNA expression.^{2, 7}

EVs as Biomarkers for Cancer Detection

The ability of EVs to encapsulate and transport a diverse array of bioactive molecules has positioned them as potential biomarkers for cancer detection. Their presence in various biological fluids, including blood, urine, tears and saliva, makes them particularly appealing for non-invasive diagnostic applications. ⁸ The following sections will elaborate on the specific attributes of EVs that qualify them as biomarkers and discuss ongoing clinical applications.

Advantages of EV-based Biomarkers

Liquid Biopsy in the True Sense

Recent studies have identified cell-specific markers expressed on the surface of circulating EVs. Technological advancements have now enabled the detection of these cell-specific markers in biofluids, allowing for the isolation and characterization of the cargo within these targeted EVs. ² This development enhances the concept of liquid biopsy, providing a more accurate and meaningful approach to cancer detection and monitoring.

Non-invasiveness

One of the main advantages of using EVs is the ability to collect them from non-invasive sources, such as blood, urine, tears or saliva, eliminating the need for invasive biopsy procedures that may cause discomfort or complications for patients. ⁹

Stability in Circulation

EVs are lipid-bound structures that effectively safeguard their cargo of bioactive compounds from degradation. This protective lipid bilayer not only enhances the stability of these molecular components but also facilitates their transport between cells, allowing for efficient intercellular communication. EVs exhibit prolonged stability in the bloodstream compared to free-floating biomolecules, reducing the likelihood of degradation before analysis.^{1, 2}

Reflective Nature

The molecular cargo within EVs can reflect the heterogeneity of tumors, including changes that may occur during treatment, thereby providing insights into treatment response and tumor evolution. ¹⁰

Clinical Applications and Evidence

The utility of EVs in cancer diagnosis is being actively researched across various malignancies. Several clinical studies have reported promising findings in the utilization of EVs as biomarkers for early cancer detection. ⁸

Lung Cancer

Studies have demonstrated that EVs derived from lung cancer cells contain specific miRNA signatures that can differentiate between lung cancer patients and healthy controls. For instance, a study by Hu et al., ¹¹ identified elevated levels of miR-21 and miR-126 in lung cancer patients’ plasma-derived EVs. The potential of EVs for distinguishing between early-stage non-small cell lung cancer and benign lung diseases is currently being investigated.

Breast Cancer

The role of EVs in breast cancer detection has also garnered attention. Several studies have reported that the levels of the oncogenic protein HER2 within circulating EVs were significantly higher in breast cancer patients compared to healthy individuals. ¹² This finding suggests a potential use of EV-derived HER2 levels as a diagnostic marker and a therapeutic target.

Pancreatic Cancer

Pancreatic cancer is known for its devastating prognosis, primarily due to late-stage diagnosis. However, EVs offer a glimmer of hope. According to a study by Melo et al. (2015), they identified a cell surface proteoglycan, glypican-1 (GPC1), specifically enriched on cancer-cell-derived EVs. Cargo signatures from circulating cancer cell-specific EVs displayed high sensitivity and specificity for detecting early-stage pancreatic cancer. These findings indicate that profiling EV-derived miRNAs may serve as a promising method for the early detection of this lethal malignancy. ¹³

Bladder Cancer

Urine-derived EVs have emerged as promising biomarkers for the early diagnosis of bladder cancer. EV presence in urine offers a non-invasive method for cancer detection, making it particularly appealing for bladder cancer, a disease known for its high recurrence rate and the need for frequent monitoring. Studies have demonstrated that the molecular cargo of urine-derived EVs can provide critical insights into the pathological state of the bladder. For instance, the presence of specific miRNAs, such as miR-21 ¹⁴ and miR-141, ¹⁵ has been linked to the diagnosis and progression of bladder cancer. Additionally, proteomic analyses of the cargo of urine-derived EVs have revealed the overexpression of certain proteins associated with bladder cancer, such as epithelial growth factor receptor (EGFR), which may serve as potential biomarkers for early detection. ¹⁶ The ease of collection and analysis of urine-derived EVs positions them as a valuable tool for clinicians in the early identification of bladder cancer, potentially improving patient outcomes through timely intervention and personalized treatment strategies.

Challenges and Future Directions

Despite the promising potential of EVs in cancer detection, several challenges must be addressed to translate these findings into clinical practice.

Standardization

The field lacks standardized protocols for the isolation, characterization, and analysis of EVs. Variability in methodologies can lead to discrepancies in results across studies. Establishing consensus guidelines will be essential for future research. ¹⁷

Validation of Biomarkers

While numerous studies have identified potential EV-based biomarkers, rigorous validation is crucial. Large-scale, multicentric clinical trials are needed to assess the diagnostic performance of these biomarkers across diverse patient populations.

Understanding Biological Dynamics

Investigating how cancer cells modulate EV production and content during tumor progression is crucial. This knowledge will enhance the interpretation of EV-based biomarkers and their clinical relevance. ¹⁰

Regulatory Approval

The pathway to regulatory approval for EV-based diagnostics remains unclear. Collaboration between researchers, clinicians, and regulatory agencies will be vital in establishing frameworks for validating and ensuring the safety and efficacy of these novel biomarkers.

Conclusion

EVs signify a significant shift in how we approach cancer diagnostics, providing a dynamic and innovative tool that bridges the gap between research and clinical application, offering a non-invasive and insightful method for early detection. As ongoing research continues to unravel the complexities of EV biology, there is great promise that EV-based biomarkers will revolutionize the way we approach early cancer diagnosis or potential risk assessment and treatment. The integration of these biomarkers into routine clinical practice has the potential to improve patient outcomes through earlier intervention, personalized treatment strategies, and enhanced monitoring of disease progression.

As we stand at the cusp of this exciting domain in oncology, it is imperative for the scientific community to collaborate across disciplines, validate findings, and address the remaining challenges. With concerted efforts, the dream of using EVs for early cancer detection can soon become a reality.